Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two encore poster presentations highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm™ (epinephrine) sublingual film will be presented at the Eastern Allergy Conference (EAC).
- WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two encore poster presentations highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm™ (epinephrine) sublingual film will be presented at the Eastern Allergy Conference (EAC).
- Taking place from May 30 through June 2, 2024, in Palm Beach, Florida, EAC features the most current information from the field's top experts on Allergy, Asthma and Immunology.
- Anaphylm is the Company’s first and only orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
- “Anaphylm has the potential to transform the treatment of severe allergic reactions, including anaphylaxis.